Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 688 across all filing types
Latest filing 2020-09-09 Report Publication Anno…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Inventiva to participate at several investor conferences in September 2020
Report Publication Announcement Classification · 99% confidence The document is a press release from Inventiva announcing that its management team will participate in five investor conferences during September 2020. It details the names, dates, times, and formats of these participation events (e.g., corporate presentations, one-on-one meetings, panel discussions). This type of announcement, which informs investors about upcoming opportunities to engage with management at industry events, is best classified as an Investor Presentation (IP) announcement or related communication, but given the specific options, it is most closely related to investor engagement activities. Since it is not a formal regulatory filing (like 10-K or IR), nor a release of financial results (ER), nor a formal presentation document itself, but rather an announcement *about* investor engagement opportunities, it fits best under the general category of Investor Presentation (IP) materials or, if interpreted as a general update on investor relations activities, potentially a Regulatory Filing (RNS) if no better fit exists. However, the content is entirely focused on upcoming investor meetings and conferences. The closest specific category that covers investor-facing materials and events is 'Investor Presentation' (IP). Since this is an announcement *about* participation, it is a precursor to an IP or a general investor relations update. Given the options, 'IP' is the most relevant theme, but 'RPA' (Report Publication Announcement) is often used for announcements about investor-facing events or materials. Since this is an announcement about management's schedule for investor engagement, and not a formal report, 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) are possibilities. Given the focus on investor conferences, 'IP' (Investor Presentation) is thematically strong, but 'RPA' is often used for announcements detailing the release or availability of investor-related information/events. I will select 'IP' as the primary theme is investor engagement/presentation opportunities, even though it's an announcement of participation rather than the presentation itself. If the document were extremely short and just linking to a presentation, RPA would be stronger. As it details multiple events, IP is a reasonable fit for the subject matter.
2020-09-09 English
Inventiva participera à plusieurs conférences investisseurs en septembre 2020
Report Publication Announcement Classification · 99% confidence The document is a press release dated September 9, 2020, announcing that the management team of Inventiva will participate in five investor conferences during September 2020. It details the names, dates, times, and formats (presentations, Q&A sessions, roundtables) of these events. This type of announcement, informing the market about management's schedule for meeting with investors and presenting company updates at external industry events, is best classified as an Investor Presentation (IP) announcement or related communication, as it directly relates to investor engagement activities. However, since the document itself is an announcement *about* future presentations rather than the presentation material itself, and it doesn't fit the strict definition of an Earnings Release (ER) or a formal regulatory filing, the most appropriate category among the provided options that covers investor-focused communications about participation in industry events is 'Investor Presentation' (IP), as these events typically involve presenting company information. Given the context of scheduling participation in investor-focused conferences, IP is the closest fit, although RPA (Report Publication Announcement) could also be considered if this were seen as announcing the *availability* of presentation materials, but here it is announcing the *schedule* of participation. I will select IP as it relates directly to investor outreach activities.
2020-09-09 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Regulatory Filings Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux" and is dated August 12, 2020. It details the status of a liquidity contract (share buyback/stabilization agreement) as of June 30, 2020, comparing it to the previous year-end. This type of announcement, which reports on the company's own share transactions under a specific agreement, aligns directly with the definition of 'Transaction in Own Shares' (POS). While it is a press release, its core subject matter is the share repurchase/stabilization activity, making POS a more specific classification than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). The document length (6524 chars) is substantial enough to be the primary report, not just a notification of one.
2020-08-12 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux" (PRESS RELEASE Semi-annual statement of the liquidity contract of the company Inventiva concluded with Kepler Cheuvreux). It reports on the status of a liquidity contract (cash and shares held by the market maker) as of June 30, 2020, comparing it to previous periods. This type of announcement, detailing financial arrangements or specific operational updates outside of core financial results (like 10-K or IR), often falls under general regulatory announcements or specific corporate actions. Since it is a press release announcing a specific, non-core financial update (liquidity contract status), and it is not a full financial report (like IR or 10-K), nor a management discussion (MDA), nor a dividend notice (DIV), the most appropriate general category for a specific, non-standard corporate update that is released publicly is 'Regulatory Filings' (RNS), as it serves as a formal public disclosure. Alternatively, because it details a specific financial arrangement (liquidity contract), it could potentially relate to 'Capital/Financing Update' (CAP), but RNS is a safer general classification for non-standard press releases. Given the options, and recognizing this is a formal, periodic disclosure about a specific financial arrangement (liquidity provision), RNS (Regulatory Filings) is the best fit as a catch-all for specific, non-core disclosures that are not covered by other specific codes like ER, IR, or DIV. It is not an announcement of a report (RPA) because it *is* the report/statement itself, albeit a very specific one.
2020-08-12 French
DESCRIPTIF DU PROGRAMME LIMITE DE RACHAT D’ACTIONS & REPRISE DU CONTRAT DE LIQUIDITE
Transaction in Own Shares Classification · 99% confidence The document is titled "PRESS RELEASE COMMUNIQUE DE PRESSE DESCRIPTIF DU PROGRAMME LIMITE DE RACHAT D'ACTIONS REPRISE DU CONTRAT DE LIQUIDITE" (Press Release Description of the Limited Share Buyback Program Resumption of the Liquidity Contract). It details the objectives, maximum amount, price, and duration of a share repurchase program authorized by the General Meeting and the Board of Directors. It also announces the resumption of the liquidity contract. Share repurchase programs and related announcements fall under the category of transactions in a company's own shares. The filing type code 'POS' (Transaction in Own Shares) is the most appropriate classification for a detailed announcement regarding a share buyback program.
2020-08-10 French
DESCRIPTION OF THE SHARE BUYBACK PROGRAM & RESUMPTION OF THE LIQUIDITY CONTRACT
Transaction in Own Shares Classification · 99% confidence The document explicitly details the terms, objectives, and authorization for a 'SHARE BUYBACK PROGRAM' and announces the 'RESUMPTION OF THE LIQUIDITY CONTRACT'. A share buyback program is a direct action taken by a company regarding its own shares, often involving the purchase or sale of those shares in the market. This aligns precisely with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance. Although it involves capital structure, the primary focus is the transaction itself, not a general financing update (CAP) or a broad capital change announcement (SHA).
2020-08-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.